CTI BioPharma Corp. [NASDAQ: CTIC] traded at a low on 09/13/22, posting a -3.40 loss after which it closed the day’ session at $6.25. The company report on August 22, 2022 that CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved on August 22, 2022, in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received options to purchase an aggregate of 40,000 shares of CTI BioPharma common stock. The options will be issued upon each employee’s grant date (the “Grant Date”), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee’s Grant Date, subject to the employee’s continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.
The results of the trading session contributed to over 3921876 shares changing hands. Over the past one week, the price volatility of CTI BioPharma Corp. stands at 5.99% while the volatility over the past one month is 6.67%.
The market cap for CTIC stock reached $700.56 million, with 114.39 million shares outstanding and 114.17 million shares in the current float. Compared to the average trading volume of 4.87M shares, CTIC reached a trading volume of 3921876 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about CTI BioPharma Corp. [CTIC]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CTIC shares is $10.74 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CTIC stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for CTI BioPharma Corp. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 01, 2022. While these analysts kept the previous recommendation, Cowen raised their target price to Outperform. The new note on the price target was released on July 07, 2022, representing the official price target for CTI BioPharma Corp. stock. Previously, the target price had yet another raise to $7, while BTIG Research analysts kept a Buy rating on CTIC stock.
The Average True Range (ATR) for CTI BioPharma Corp. is set at 0.46, with the Price to Sales ratio for CTIC stock in the period of the last 12 months amounting to 47.98.
How has CTIC stock performed recently?
CTI BioPharma Corp. [CTIC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.57. With this latest performance, CTIC shares gained by 7.94% in over the last four-week period, additionally plugging by 49.88% over the last 6 months – not to mention a rise of 99.68% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTIC stock in for the last two-week period is set at 50.01, with the RSI for the last a single of trading hit 49.53, and the three-weeks RSI is set at 50.42 for CTI BioPharma Corp. [CTIC]. The present Moving Average for the last 50 days of trading for this stock 6.34, while it was recorded at 6.37 for the last single week of trading, and 4.39 for the last 200 days.
CTI BioPharma Corp. [CTIC]: Deeper insight into the fundamentals
Return on Equity for this stock declined to -447.11, with Return on Assets sitting at -149.85.
CTI BioPharma Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.60 and a Current Ratio set at 3.60.
Insider trade positions for CTI BioPharma Corp. [CTIC]
There are presently around $555 million, or 80.00% of CTIC stock, in the hands of institutional investors. The top three institutional holders of CTIC stocks are: STATE STREET CORP with ownership of 9,849,528, which is approximately 3530.025% of the company’s market cap and around 0.21% of the total institutional ownership; BVF INC/IL, holding 8,929,690 shares of the stock with an approximate value of $55.81 million in CTIC stocks shares; and NEA MANAGEMENT COMPANY, LLC, currently with $50.3 million in CTIC stock with ownership of nearly 12.699% of the company’s market capitalization.
Positions in CTI BioPharma Corp. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 87 institutional holders increased their position in CTI BioPharma Corp. [NASDAQ:CTIC] by around 36,279,454 shares. Additionally, 38 investors decreased positions by around 6,808,982 shares, while 13 investors held positions by with 45,746,808 shares. The mentioned changes placed institutional holdings at 88,835,244 shares, according to the latest SEC report filing. CTIC stock had 49 new institutional investments in for a total of 10,829,097 shares, while 17 institutional investors sold positions of 1,828,880 shares during the same period.